Related references
Note: Only part of the references are listed.Extensive functional evaluation of exon 20 insertion mutations of EGFR
Takeshi Hirose et al.
LUNG CANCER (2021)
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies
Noboru Yamamoto et al.
INVESTIGATIONAL NEW DRUGS (2020)
High-throughput functional evaluation of BRCA2 variants of unknown significance
Masachika Ikegami et al.
NATURE COMMUNICATIONS (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Landscape and function of multiple mutations within individual oncogenes
Yuki Saito et al.
NATURE (2020)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai et al.
CELLS (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Masaaki Nagano et al.
CLINICAL CANCER RESEARCH (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor- Positive Breast Tumors
Jingqin Luo et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
Shinji Kohsaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases
Huaibin Chen et al.
ELIFE (2017)
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Paul K. Paik et al.
CLINICAL CANCER RESEARCH (2017)
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
New and emerging targeted treatments in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
LANCET (2016)
Mechanism of FGF receptor dimerization and activation
Sarvenaz Sarabipour et al.
NATURE COMMUNICATIONS (2016)
FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer
Willemijn S. M. E. Theelen et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2016)
Myeloid and Lymphoid Neoplasm With Abnormalities of FGFR1 Presenting With Trilineage Blasts and RUNX1 Rearrangement: A Case Report and Review of Literature
Kirthi R. Kumar et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer
Anna Fischbach et al.
HISTOPATHOLOGY (2015)
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
Gottfried E. Konecny et al.
LANCET ONCOLOGY (2015)
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
R. Dienstmann et al.
ANNALS OF ONCOLOGY (2014)
FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non-Small Cell Lung Cancer
Rui Wang et al.
CLINICAL CANCER RESEARCH (2014)
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I. Milowsky et al.
EUROPEAN JOURNAL OF CANCER (2014)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
FGFR1 Mutations in Rosette-Forming Glioneuronal Tumors of the Fourth Ventricle
Marco Gessi et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2014)
Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene
Angel Alvarez et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2014)
Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer
Eva Pros et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Molecular Mechanisms of Fibroblast Growth Factor Signaling in Physiology and Pathology
Artur A. Belov et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Yi-Mi Wu et al.
CANCER DISCOVERY (2013)
The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
Sara A. Byron et al.
NEOPLASIA (2013)
FGFR2 gene amplification and clinicopathological features in gastric cancer
K. Matsumoto et al.
BRITISH JOURNAL OF CANCER (2012)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh et al.
SCIENCE (2012)
Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease
Nobuyuki Itoh et al.
JOURNAL OF BIOCHEMISTRY (2011)
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Nicholas Turner et al.
CANCER RESEARCH (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle-Invasive Bladder Cancer
Tahlita C. M. Zuiverloon et al.
CLINICAL CANCER RESEARCH (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
The Selectivity of Receptor Tyrosine Kinase Signaling Is Controlled by a Secondary SH2 Domain Binding Site
Jae Hyun Bae et al.
CELL (2009)
Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner
E. di Martino et al.
ONCOGENE (2009)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases
Huaibin Chen et al.
MOLECULAR CELL (2007)
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
D. C. Tomlinson et al.
JOURNAL OF PATHOLOGY (2007)
The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling
PMJ Lievens et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation
T Akagi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum
PMJ Lievens et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Share Paper
